Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Rating of “Moderate Buy” by Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO) has received a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $8.50.

A number of research firms recently weighed in on ANRO. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research note on Friday, March 21st. Wedbush reiterated a “neutral” rating and set a $4.00 price target on shares of Alto Neuroscience in a report on Thursday, May 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Alto Neuroscience in a research report on Thursday, June 26th.

Alto Neuroscience Stock Up 2.0%

Shares of NYSE ANRO opened at $2.35 on Friday. The stock has a market cap of $63.48 million, a P/E ratio of -1.00 and a beta of 1.65. The business’s fifty day simple moving average is $2.47 and its 200-day simple moving average is $3.05. Alto Neuroscience has a 12-month low of $1.60 and a 12-month high of $17.55. The company has a current ratio of 22.53, a quick ratio of 22.53 and a debt-to-equity ratio of 0.15.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.06. As a group, equities analysts predict that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE boosted its holdings in Alto Neuroscience by 63.7% in the fourth quarter. Bank of America Corp DE now owns 56,532 shares of the company’s stock valued at $239,000 after purchasing an additional 22,007 shares in the last quarter. Northern Trust Corp raised its holdings in Alto Neuroscience by 198.1% during the fourth quarter. Northern Trust Corp now owns 587,135 shares of the company’s stock worth $2,484,000 after purchasing an additional 390,190 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Alto Neuroscience by 885.4% during the 4th quarter. BNP Paribas Financial Markets now owns 42,520 shares of the company’s stock worth $180,000 after buying an additional 38,205 shares during the last quarter. Cantor Fitzgerald L. P. acquired a new position in shares of Alto Neuroscience in the 4th quarter valued at $1,575,000. Finally, Jane Street Group LLC boosted its holdings in shares of Alto Neuroscience by 72.0% in the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock valued at $79,000 after buying an additional 7,783 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.